NZ757965A - Liquid formulation of anti-tnf alpha antibody - Google Patents

Liquid formulation of anti-tnf alpha antibody

Info

Publication number
NZ757965A
NZ757965A NZ757965A NZ75796518A NZ757965A NZ 757965 A NZ757965 A NZ 757965A NZ 757965 A NZ757965 A NZ 757965A NZ 75796518 A NZ75796518 A NZ 75796518A NZ 757965 A NZ757965 A NZ 757965A
Authority
NZ
New Zealand
Prior art keywords
formulation
adalimumab
formulations
arginine
concentration
Prior art date
Application number
NZ757965A
Other languages
English (en)
Inventor
Sora Yun
Youn Kyung Ko
Jin Eon So
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ757965(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of NZ757965A publication Critical patent/NZ757965A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
NZ757965A 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibody NZ757965A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (fr) 2017-03-16 2018-03-16 Formulation liquide d'anticorps anti-tnf alpha

Publications (1)

Publication Number Publication Date
NZ757965A true NZ757965A (en) 2022-07-01

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ757965A NZ757965A (en) 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibody

Country Status (14)

Country Link
JP (2) JP7109849B2 (fr)
KR (2) KR20180106974A (fr)
CN (1) CN110621303A (fr)
AU (1) AU2018236651B2 (fr)
CO (1) CO2019010860A2 (fr)
MA (1) MA46988A1 (fr)
MX (1) MX2019010895A (fr)
MY (1) MY197202A (fr)
NZ (1) NZ757965A (fr)
PH (1) PH12019502075A1 (fr)
RU (1) RU2756619C2 (fr)
UA (1) UA123847C2 (fr)
WO (1) WO2018169348A1 (fr)
ZA (1) ZA201906696B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120241997A (zh) * 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN113727730A (zh) * 2019-03-18 2021-11-30 阿尔沃科技Hf公司 高浓度TNFα抗体的含水制剂
TW202519263A (zh) * 2019-03-21 2025-05-16 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
EP4108258A4 (fr) * 2020-02-20 2024-03-06 Bio-Thera Solutions, Ltd. Préparation d'anticorps anti-tnf-alpha, sa méthode de préparation et son utilisation
JP2023533704A (ja) * 2020-07-13 2023-08-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 高濃度タンパク質製剤用の粘度低減賦形剤及びそれらの組み合わせ
WO2022178114A1 (fr) * 2021-02-17 2022-08-25 Aptevo Research And Development Llc Compositions comprenant des protéines de liaison à 4-1bb et ox40 et leurs procédés d'utilisation
JPWO2025013783A1 (fr) 2023-07-07 2025-01-16

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821865B2 (en) * 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
JP2015509526A (ja) * 2012-03-07 2015-03-30 カディラ ヘルスケア リミティド 医薬製剤
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
BR112015017619A2 (pt) * 2013-01-24 2017-11-21 Glaxosmithkline Ip Dev Ltd formulação líquida, uso de uma formulação, e, kit
TW201513882A (zh) 2013-03-15 2015-04-16 Bayer Healthcare Llc 抗－催乳激素受體抗體調配物
WO2015134406A1 (fr) 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Préparations aqueuses stables de protéine recombinée
WO2015151115A1 (fr) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Composition pharmaceutique liquide d'adalimumab
PT2946765T (pt) * 2014-05-23 2016-11-10 Ares Trading Sa Composição farmacêutica líquida
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US20180016333A1 (en) * 2015-01-28 2018-01-18 Mabxience, S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016162819A1 (fr) * 2015-04-07 2016-10-13 Lupin Limited Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha

Also Published As

Publication number Publication date
JP7109849B2 (ja) 2022-08-01
RU2019130728A (ru) 2021-04-16
CN110621303A (zh) 2019-12-27
MY197202A (en) 2023-05-31
KR102342292B1 (ko) 2021-12-24
MA46988A1 (fr) 2020-06-30
AU2018236651B2 (en) 2020-12-10
RU2756619C2 (ru) 2021-10-04
WO2018169348A1 (fr) 2018-09-20
AU2018236651A1 (en) 2019-10-31
KR20180106974A (ko) 2018-10-01
BR112019019162A2 (pt) 2020-04-14
PH12019502075A1 (en) 2020-09-14
CO2019010860A2 (es) 2020-01-17
UA123847C2 (uk) 2021-06-09
MX2019010895A (es) 2019-11-05
JP2020510079A (ja) 2020-04-02
RU2019130728A3 (fr) 2021-04-16
JP2022097600A (ja) 2022-06-30
KR20200096472A (ko) 2020-08-12
ZA201906696B (en) 2020-08-26

Similar Documents

Publication Publication Date Title
AU2018236651B2 (en) Liquid formulation of anti-TNF alpha antibody
AU2007338791B2 (en) Stable buffered formulations containing polypeptides
AU2007307107B2 (en) Stable antibody formulations
CA2515444C (fr) Preparation d'immunoglobuline et son procede de production
CA2976298A1 (fr) Formulation liquide stable pour des anticorps monoclonaux
JP2020063261A (ja) ＴＮＦＲ及びＦｃ領域を含む融合タンパク質の液体製剤
US20250043027A1 (en) Formulation of highly concentrated pharmacologically active antibody
EP4717712A2 (fr) Formulation de vedolizumab
WO2022151940A1 (fr) Composition pharmaceutique stable de pertuzumab
AU2024349247A1 (en) Stable liquid formulation of anti-il-23 antibody
US20210347877A1 (en) Pharmaceutical composition comprising antibody, device comprising same, and use thereof
BR112019019162B1 (pt) Formulação líquida de um anticorpo anti-tnf-a e método parapreparar a formulação líquida
WO2025255300A1 (fr) Formulations pour anticorps anti-n3pglu amyloïde bêta
US11236146B2 (en) Stable pharmaceutical formulation
AU2014201388B2 (en) Stable Buffered Formulations Containing Polypeptides

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2024 BY MARKPRO GLOBAL COMPANY

Effective date: 20230221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2025 BY MARKPRO GLOBAL COMPANY

Effective date: 20240219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2026 BY MARKPRO GLOBAL COMPANY

Effective date: 20250221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2027 BY MARKPRO GLOBAL COMPANY

Effective date: 20260305